ライフサイエンスコーパス: HIV vaccine

1 nd the focus for design of an antibody-based HIV vaccine.

2 iasm for a neutralizing antibody (nAb)-based HIV vaccine.

3 controllers may hold the key to an effective HIV vaccine.

4 bodies is critical for the development of an HIV vaccine.

5 otential to be developed into a prophylactic HIV vaccine.

6 ly novel approach to developing an effective HIV vaccine.

7 mportant for the development of an effective HIV vaccine.

8 ologic prime to aid protection by a putative HIV vaccine.

9 ound CD40L serves as a novel adjuvant for an HIV vaccine.

10 to be critical constituents in an effective HIV vaccine.

11 can contribute to the design of an effective HIV vaccine.

12 ccinology offer new promise for an effective HIV vaccine.

13 n (and exclusion) of specific epitopes in an HIV vaccine.

14 odeled after the moderately protective RV144 HIV vaccine.

15 rotective responses elicited by an effective HIV vaccine.

16 ent a beneficial component of an efficacious HIV vaccine.

17 o accelerate the development of an effective HIV vaccine.

18 ion and to aid in the design of an effective HIV vaccine.

19 e development of an effective antibody-based HIV vaccine.

20 ons for the continued quest for an effective HIV vaccine.

21 offers great promise for advancing toward an HIV vaccine.

22 aluation of VZV as a potential vector for an HIV vaccine.

23 entual design of an effective antibody-based HIV vaccine.

24 a daunting problem for the development of an HIV vaccine.

25 nses that might be desirable in a protective HIV vaccine.

26 the development of an effective and durable HIV vaccine.

27 HIV presents a key challenge for creating an HIV vaccine.

28 rus (HIV) immune responses is the goal of an HIV vaccine.

29 l immunogen design, including a T cell-based HIV vaccine.

30 promise as a unique approach to an effective HIV vaccine.

31 ral new candidates for a potent T-cell-based HIV vaccine.

32 for the development of a globally effective HIV vaccine.

33 n important target for the development of an HIV vaccine.

34 ion can help guide the rational design of an HIV vaccine.

35 ve promise to assist in the development of a HIV vaccine.

36 tem and our best hope of finally creating an HIV vaccine.

37 bject of intense study in efforts to produce HIV vaccines.

38 l in the design of stabilized envelope-based HIV vaccines.

39 newing hope of developing carbohydrate-based HIV vaccines.

40 a role for eliciting ADCC-mediating IgG1 in HIV vaccines.

41 on against further use of the Ad5 vector for HIV vaccines.

42 e targets that would augment the efficacy of HIV vaccines.

43 de important insights for the development of HIV vaccines.

44 l challenge in the preclinical evaluation of HIV vaccines.

45 pment of next-generation vaccines, including HIV vaccines.

46 ent RV144 clinical trial, which combined two HIV vaccines.

47 development of therapeutic and preventative HIV vaccines.

48 be considered a new approach for preventive HIV vaccines.

49 erequisites for clinical trials of candidate HIV vaccines.

50 on, which has implications for the design of HIV vaccines.

51 st new strategies for design and delivery of HIV vaccines.

52 eveloping antigens that could serve as novel HIV vaccines.

53 inging new insights for the design of future HIV vaccines.

54 r the design, testing, and implementation of HIV vaccines.

55 tion for both subtype-specific and universal HIV vaccines.

56 re HIV vaccine trials and the development of HIV vaccines.

57 1 is a major challenge to the development of HIV vaccines.

58 ortant new direction in future design of new HIV vaccines.

59 velopment of a human immunodeficiency virus (HIV) vaccine.

60 The development of a preventative HIV vaccine able to elicit broadly neutralizing antibodi

61 Our results suggest that HIV vaccine adjuvants may differentially modulate immune

62 fficacy trial testing the combination of the HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E to prev

63 pment has provided renewed impetus toward an HIV vaccine and led directly to the development of novel

64 ransmission and in the design and testing of HIV vaccine and microbicide candidates.

65 understanding of how to design an effective HIV vaccine and novel therapeutics to eliminate the vira

66 ral blood B cells of recipients of the RV144 HIV vaccine and showed that these antibodies neutralized

67 rtant implications for the development of an HIV vaccine and the design of diagnostic, resistance, an

68 hich should inform the design of efficacious HIV vaccines and immunotherapies.

69 le to provide a platform to assess candidate HIV vaccines and other immunotherapeutic strategies.

70 need to be answered to develop a protective HIV vaccine, and the immediate need to harness a much br

71 urfaces, FcRn might be useful for delivering HIV vaccine antigens across mucosal epithelial barriers

72 Many candidate HIV vaccines are designed to primarily elicit T cell res

73 s a major challenge to the development of an HIV vaccine, as well as diagnostic, drug resistance, and

74 This study tested if delivering HIV vaccines at mucosa or in the muscle makes a differen

75 erous attempts over many years to develop an HIV vaccine based on classical strategies, none has conv

76 resses the challenge to develop an effective HIV vaccine but also emphasizes that unconventional and

77 bbit and rhesus macaque models to accelerate HIV vaccine candidate testing in human trials.

78 protein warrants further investigation as an HIV vaccine candidate, as a stand-alone protein, or as a

79 Here, we generated two poxvirus-based HIV vaccine candidates (NYVAC and ALVAC vectors) express

80 tively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response

81 challenges, one of which is the inability of HIV vaccine candidates evaluated thus far to elicit prod

82 We have generated two novel NYVAC-based HIV vaccine candidates expressing HIV-1 clade C trimeric

83 egree to which this problem extends to other HIV vaccine candidates is not known.

84 and b12H mice should be useful in optimizing HIV vaccine candidates to elicit a neutralizing response

85 hlighted the need for further improvement of HIV vaccine candidates, formulation, and vaccine regimen

86 ot protective, and despite immunogenicity of HIV vaccine candidates, human trials have exclusively yi

87 ures, provides insights to advance design of HIV vaccine candidates.

88 he need for further improvements to evaluate HIV vaccine candidates.

89 centrations, inspiring efforts to develop an HIV vaccine capable of eliciting bNAb responses.

90 HIV vaccine research focused on designing an HIV vaccine capable of eliciting V2-focused, polyfunctio

91 timmunization.IMPORTANCE Attempts to develop HIV vaccines capable of inducing potent and durable B-ce

92 4, they generate testable hypotheses for the HIV vaccine community and they highlight the importance

93 Pediatric HIV vaccines constitute a core component of such efforts

94 zation with neutralizing Abs suggest that an HIV vaccine could be efficacious were it able to elicit

95 A pediatric HIV vaccine could reduce the number of these ongoing inf

96 (Ad5)-vectored human immunodeficiency virus (HIV) vaccine could prevent HIV acquisition and/or reduce

97 denovirus serotype 5-vectored (Ad5-vectored) HIV vaccine demonstrated increased HIV risk in individua

98 These findings will inform HIV vaccine design by providing testable correlates of p

99 A guiding principle for HIV vaccine design has been that cellular and humoral im

100 protection against HIV is a central goal of HIV vaccine design, understanding the nature of maternal

101 re throughout, making it a stable target for HIV vaccine design.

102 that triggered it, providing a template for HIV vaccine design.

103 value of the polyvalent formulation in this HIV vaccine design.

104 e cells has the potential to inform rational HIV vaccine design.

105 -1 infection, with positive implications for HIV vaccine design.

106 phenotype may provide important insights for HIV vaccine design.

107 ection, which has important implications for HIV vaccine design.

108 opeptides are therefore of great interest in HIV vaccine design.

109 vel approaches to preventive and therapeutic HIV vaccine design.

110 ody responses and therefore crucial for anti-HIV vaccine design.

111 d, protective antibodies remains a hurdle to HIV vaccine design.

112 arch symposium on humanized mouse models for HIV vaccine design.

113 ed individuals, define critical epitopes for HIV vaccine design.

114 g certain epitope targets and strategies for HIV vaccine design.

115 e engineering of specific Env glycoforms for HIV vaccine design.

116 on and antibody development is important for HIV vaccine design.

117 ortant goal of human immunodeficiency virus (HIV) vaccine design is identification of strategies that

118 evant issue for candidate germline-targeting HIV vaccine designs because of the in vivo rarity of nai

119 Our data provide important information for HIV vaccine designs that aim for effective and balanced

120 l and highlights the increasing challenge to HIV vaccine development and diagnostic, drug resistance,

121 nteraction should be further investigated in HIV vaccine development and other prophylactic vaccine a

122 population should be further investigated in HIV vaccine development as a novel correlate of immunity

123 ction.IMPORTANCE Our results are relevant to HIV vaccine development efforts because they suggest tha

124 However, HIV vaccine development has been hampered by significant

125 A goal of HIV vaccine development is to elicit antibodies with neu

126 A central effort in HIV vaccine development is to generate protective broadl

127 ibody durability, is the major challenge for HIV vaccine development, regardless of the immunogen or

128 ade immunogens with the potential to advance HIV vaccine development.

129 lizing antibodies (bNAbs) is a major goal of HIV vaccine development.

130 zing antibodies (bnAbs) is a primary goal of HIV vaccine development.

131 rational design of glycopeptide antigens for HIV vaccine development.

132 e of this unique non-human primate model for HIV vaccine development.

133 ate of HIV-1 control that may be relevant to HIV vaccine development.

134 carbohydrate-based immunogens and hasten the HIV vaccine development.

135 l basis for gp41 antigen design suitable for HIV vaccine development.

136 g activity of the mAbs, long sought goals in HIV vaccine development.

137 create an antigenic conformation optimal for HIV vaccine development.

138 ex and evolving, and is a major challenge to HIV vaccine development.

139 replication provide a useful model to inform HIV vaccine development.

140 mma receptor genetic variations may modulate HIV vaccine effects and immune function after HIV vaccin

141 Mucosal immunization may enhance HIV vaccine efficacy by eliciting protective responses a

142 ble capacity to evade host immune responses, HIV vaccine efficacy may benefit from the induction of b

143 The RV 144 HIV vaccine efficacy study showed a reduction in HIV-1 i

144 relates of protection/immunity' in the RV144 HIV vaccine efficacy trial that are missed by other meth

145 orts of the partially efficacious Thai RV144 HIV vaccine efficacy trial.

146 -populations in Uganda, during two Simulated HIV Vaccine Efficacy trials (SiVETs).

147 Human HIV vaccine efficacy trials have not generated meaningfu

148 nation regimens.IMPORTANCE The evaluation of HIV vaccine efficacy trials indicates that protection wo

149 induction of preventive antibodies in future HIV vaccine efficacy trials.

150 All human immunodeficiency virus (HIV) vaccine efficacy trials to date have ended in failu

151 bodies to V2 are also important hallmarks of HIV-vaccine efficacy in humans will require further stud

152 me of neutralization broadening as effective HIV vaccine elements.

153 gned mosaic antigens increase the breadth of HIV vaccine-elicited immunity.

154 monoclonal antibodies (MAbs) in the current HIV vaccine field are generated from HIV-1-infected peop

155 standing of HIV-2 biology is relevant to the HIV vaccine field because a substantial proportion of in

156 CC) responses are of growing interest in the HIV vaccine field but current cell-based assays are usua

157 The HIV vaccine field now recognizes the potential importanc

158 erved in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the re

159 essful example of reverse vaccinology in the HIV vaccine field with rationally designed epitope scaff

160 Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antib

161 Therefore, it may be possible to direct HIV vaccine-generated responses to associate with MUC16

162 y neutralizing antibodies (bnAbs) is a major HIV vaccine goal.

163 neutralizing antibodies (bnAbs) is a primary HIV vaccine goal.

164 s that have been assessed for development of HIV vaccines have included purified envelope (Env) prote

165 ely, human trials of immunodeficiency virus (HIV) vaccine have shown only marginal efficacy.

166 the virus that may be exploited in designing HIV vaccine immunogens.

167 otential site to target and incorporate into HIV vaccine immunogens.

168 uld facilitate development of an efficacious HIV vaccine.IMPORTANCE The modest HIV protection observe

169 wed efforts to develop a CD8(+) T cell-based HIV vaccine in conjunction with B cell vaccine efforts.

170 al model to evaluate the added benefit of an HIV vaccine in the context of goals to increase rates of

171 (SHIVs) for the evaluation of candidate anti-HIV vaccines in nonhuman primates.

172 6 vector-based human immunodeficiency virus (HIV) vaccine in humans.

173 effective SIV/human immunodeficiency virus (HIV) vaccine in preclinical testing.

174 e safety and immunogenicity of a multivalent HIV vaccine including either DNA or NYVAC vectors alone

175 cteristics of anti-HIV bNAbs, we designed an HIV vaccine incorporating the molecular adjuvants BAFF (

176 sess how HLA-I-associated adaptation affects HIV vaccine-induced CD8 T-cell responses in 2 past vacci

177 e evaluate the use of adoptively transferred HIV vaccine-induced subtype C Env-specific CTLs in a mac

178 s diseases such as tuberculosis, malaria and HIV, vaccines inducing greater T cell responses are requ

179 Development of an HIV vaccine is critical for control of the HIV pandemic,

180 Development of an HIV vaccine is desperately needed to control new infecti

181 The key to an effective HIV vaccine is development of an immunogen that elicits

182 Development of an HIV vaccine is of vital importance for prevention of new

183 A major challenge in the development of an HIV vaccine is that of contending with the extensive seq

184 a broadly neutralizing antibody (bnAb)-based HIV vaccine is the activation of appropriate B cell prec

185 A measure of the efficacy of a HIV vaccine is the neutralization breadth of the antibod

186 The goal of an HIV vaccine is to generate robust and durable protective

187 At present, the product pipeline for HIV vaccines is insufficient and is limited by inadequat

188 Accordingly, a primary goal for HIV vaccines is to enhance the magnitude and breadth of

189 f a successful human immunodeficiency virus (HIV) vaccine is an immunogen that can generate broadly c

190 Developing a human immunodeficiency virus (HIV) vaccine is critical to end the global acquired immu

191 nd therapeutic human immunodeficiency virus (HIV) vaccines is the inability of viral envelope glycopr

192 immunogenic proteins and peptides in future HIV vaccines may act as a critical cornerstone for enhan

193 that induction of this cell subset by future HIV vaccines may be important for narrowing possible rou

194 s now conceivable that an antibody-dependent HIV vaccine might be possible, given the discovery of HI

195 ll, our results suggest that a well-designed HIV vaccine might both reduce the rate of acquisition an

196 ta suggest that efforts toward developing an HIV vaccine might consider eliciting protective HIV anti

197 -protein boost human immunodeficiency virus (HIV) vaccine modalities as a strategy to induce protecti

198 An effective HIV vaccine must elicit immune responses that recognize

199 ons are used to evaluate the Abs elicited by HIV vaccines or the bioaccumulation following immunoprop

200 Our previous studies demonstrated that in an HIV vaccine phase I trial, the DP6-001 trial, a polyvale

201 the lack of efficacy of a recently conducted HIV vaccine phase IIb trial, despite induction of robust

202 f VISP varied substantially across different HIV vaccine product types: 399 of 460 (86.7%; 95% CI, 83

203 ing antibodies are thought to be crucial for HIV vaccine protection, but studies in animal models sug

204 ctive Ab response is considered critical for HIV vaccine protective efficacy.

205 The induction of VISP in HIV vaccine recipients is common, especially with vaccin

206 o track Ag-specific plasmablast responses in HIV-vaccine recipients over a period of 42 d and perform

207 cy trials of adenovirus 5-vectored candidate HIV vaccines [recombinant Ad5 (rAd5)-HIV] were halted fo

208 BACKGROUNDRV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans.

209 In this study, we describe a novel HIV vaccine regimen that induces potent IgA responses in

210 ial of a DNA/recombinant adenovirus 5 (rAd5) HIV vaccine regimen.

211 a prime-boost human immunodeficiency virus (HIV) vaccine regimen conferred approximately 30% protect

212 Hence, SIV/HIV vaccine regimens comprising CE pDNA prime and CE+gag

213 The development of an effective HIV vaccine remains a global necessity for preventing HI

214 ver 3 decades of research, an effective anti-HIV vaccine remains elusive.

215 Abs) has provided an enormous impetus to the HIV vaccine research and to entire immunology.

216 We propose here that HIV vaccine research could greatly benefit from the stud

217 This result has fueled a decade of HIV vaccine research focused on designing an HIV vaccine

218 tibodies to HIV has been a major obstacle to HIV vaccine research since the early days of the epidemi

219 ant (CD4BD) of gp120, a central objective in HIV vaccine research, has been alternately ascribed to i

220 nt toward a need for novel methodologies for HIV vaccine research.

221 ould have important implications for ongoing HIV vaccine research.

222 ralizing antibodies has been a major goal of HIV vaccine research.

223 lizing antibodies (bNAbs) is a major goal in HIV vaccine research.

224 f new-generation HIV-1 bNAbs has invigorated HIV vaccine research.

225 This suggests that a universal HIV vaccine should be possible.

226 d they also contribute to the notion that an HIV vaccine should stimulate the production of ADCC-medi

227 HIV vaccines should elicit immune responses at both the

228 st infection by viruses such as influenza or HIV, vaccines should elicit antibodies that bind conserv

229 wever, three efficacy trials of Ad5-vectored HIV vaccines showed no protection.

230 n of functional gp120-specific antibodies by HIV vaccine strategies.

231 ghts this epitope as an important target for HIV vaccine strategies.

232 an important surrogate model for evaluating HIV vaccine strategies.

233 gnificant impact on future public health and HIV vaccine strategies.

234 velope CD4 binding site are a major focus of HIV vaccine strategies.

235 inclusion in subtype-specific and universal HIV vaccine strategies.IMPORTANCE The identification of

236 evaluation of human immunodeficiency virus (HIV) vaccine strategies in rhesus macaques.

237 that point the way forward for an effective HIV vaccine strategy.

238 the potential target populations for future HIV vaccine studies examined the prevalence of HIV infec

239 The goals of preclinical HIV vaccine studies in nonhuman primates are to develop

240 me, information about hMabs from other human HIV vaccine studies is very limited.

241 potential mechanistic significance in future HIV vaccine studies.

242 hod to generate more diverse SIV strains for HIV vaccine studies.

243 or and insert-specific CD4 T cells in future HIV vaccine studies.

244 While development of an HIV vaccine that can induce neutralizing antibodies rema

245 e very strongly, supporting the quest for an HIV vaccine that induces potent bnAbs.

246 boost to an already well-established DNA/MVA HIV vaccine that is currently being tested in the clinic

247 ces to the draining lymph nodes may allow an HIV vaccine that produces immunity in these lymph nodes

248 A HIV vaccine that provides mucosal immunity is urgently n

249 ired to inform the development of a maternal HIV vaccine that will enhance these responses during pre

250 ersonalized approach to a therapeutic T-cell HIV vaccine that would provide antigens with an excellen

251 s and provide guidance in the development of HIV vaccines that effectively block cell-associated HIV

252 p a successful human immunodeficiency virus (HIV) vaccine that is capable of preventing infection.

253 imal model for human immunodeficiency virus (HIV) vaccines that elicit CD8(+) T cell responses.

254 ell specimens from the ALVAC+AIDSVAX (RV144) HIV vaccine trial associated with protective antibody re

255 ine staining (ICS) data set from a published HIV vaccine trial focused on detecting rare, antigen-spe

256 ve capacity is warranted.IMPORTANCE The only HIV vaccine trial for which protective efficacy was dete

257 protection in a moderately successful RV144 HIV vaccine trial in humans and highlight the need for t

258 The RV144 HIV vaccine trial included a recombinant HIV glycoprotei

259 Data from the RV144 HIV vaccine trial indicated that gp120 V2 antibodies wer

260 ntive HIV-1 vaccine efficacy trials: (i) the HIV Vaccine Trial Network (HVTN) 502/Step trial, (ii) th

261 The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of a vac

262 cited by natural infection or vaccination in HIV vaccine trial subjects.

263 quisition risk identified in RV144, the only HIV vaccine trial to date to show any efficacy.

264 The only clinical HIV vaccine trial to date to show significant efficacy (

265 In the RV144 gp120 HIV vaccine trial, decreased transmission risk was corre

266 ol data from the first moderately protective HIV vaccine trial, RV144, pointed to mechanistic insight

267 relate with protection in the only effective HIV vaccine trial, the administration of preformed mucos

268 The results of the RV144 HIV vaccine trial, which demonstrated a rapid waning of

269 nism of the protection observed in the RV144 HIV vaccine trial.

270 ndividuals from HIV acquisition in the RV144 HIV vaccine trial.

271 ble for the protection observed in the RV144 HIV vaccine trial.

272 ould be considered in the analysis of future HIV vaccine trials and the development of HIV vaccines.

273 METHODS AND HIV Vaccine Trials Network (HVTN) 104 was designed to ev

274 HIV Vaccine Trials Network (HVTN) 111 tested DNA plasmid

275 esponse markers as correlates of risk in the HIV Vaccine Trials Network (HVTN) 505 HIV-1 vaccine effi

276 HIV Vaccine Trials Network (HVTN) 505 was a phase 2b eff

277 HIV Vaccine Trials Network (HVTN) studies 070 and 080 we

278 inistration order of heterologous vectors in HIV Vaccine Trials Network 078 (HVTN 078), a randomized,

279 HIV Vaccine Trials Network 083 tested whether cellular i

280 The HIV Vaccine Trials Network and the Statistical Center fo

281 Future HIV vaccine trials should recognise potential interactio

282 ding, refining, and improving the outcome of HIV vaccine trials, in which relevant immune responses a

283 ips among humoral responses elicited in four HIV vaccine trials.

284 de insight into the limited efficacy seen in HIV vaccine trials.

285 ring HLA alleles and host immune genetics in HIV vaccine trials.

286 the interest in inducing such Abs in future HIV vaccine trials.

287 protection in human immunodeficiency virus (HIV) vaccine trials are essential to vaccine design.

288 Most of the current HIV vaccines under development use the i.m. route for im

289 profile and makes it an attractive candidate HIV vaccine vector.

290 IL-1beta and make it an attractive candidate HIV vaccine vector.

291 and CMV, two viruses that have been used as HIV vaccine vectors.

292 he continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (pre

293 Studies suggest that a relevant HIV vaccine will likely need to induce broad cellular an

294 The development of an HIV vaccine will require a more precise understanding of

295 An effective human immunodeficiency virus (HIV) vaccine will likely need to reduce mucosal transmis

296 An efficacious human immunodeficiency virus (HIV) vaccine will likely require induction of both mucos

297 of native Env.IMPORTANCE Development of any HIV vaccine with a protein component (for either priming

298 tions for the final production of a clinical HIV vaccine with Env glycoprotein components.IMPORTANCE

299 y be one method by which to make an improved HIV vaccine with higher efficacy than that seen in the R

300 ) prime-boost human immuonodeficiency virus (HIV) vaccine, with intramuscular DNA delivery by either